证券代码： 002399 证券简称：海普瑞 公告编号： 2025-034 深圳市海普瑞药业集团股份有限公司 关于独立董事任期届满离任暨补选独立董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于独立董事任期届满离任的情况 根据《上市公司独立董事管理办法》等有关规定，独立董事在同一上市公司 连续任职时间不得超过六年。深圳市海普瑞药业集团股份有限公司（以下简称"公 司"）现任独立董事吕川先生连续任职时间即将届满六年。根据前述规定，届满 离任后，吕川先生将不再担任包括公司第六届董事会独立董事及董事会专门委员 会相应职务（包括提名委员会主任委员、审计委员会委员及战略委员会委员）在 内的任何职务。截至本公告披露日，吕川先生未持有公司股份，不存在应当履行 而未履行的承诺事项。 根据《深圳证券交易所股票上市规则》《上市公司独立董事管理办法》等相 关规定，吕川先生的离任将在公司股东会选举产生新任独立董事后生效。在新任 独立董事选举产生前，吕川先生将继续履行独立董事及董事会各专门委员会委员 的相关职责。 吕川先生在担任公司独立董事期间，勤勉尽责、独立公正，为公司 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 2 | 《股东会议事规则》 | 股东会 | | --- | --- | --- | | 3 | 《董事会议事规则》 | 股东会 | | 4 | 《独立董事工作制度》 | 股东会 | | 5 | 《关联交易决策制度》 | 股东会 | | 6 | 《对外提供财务资助管理制度》 | 股东会 | | 7 | 《董事和高级管理人员薪酬与绩效考核制度》 | 股东会 | | 8 | 《对外担保管理制度》 | 股东会 | | 9 | 《委托理财管理制度》 | 股东会 | | 10 | 《募集资金使用管理办法》 | 董事会 | | 11 | 《会计师事务所选聘制度》 | 董事会 | | 12 | 《董事会专门委员会工作细则》 | 董事会 | | 13 | 《董事和高级管理人员离职管理制度》 | 董事会 | | 14 | 《董事和高级管理人员所持公司股份及其变动管理制度》 | 董事会 | | 15 | 《内部审计管理制度》 | 董事会 | | 16 | 《信息披露事务管理制度》 | 董事会 | | 17 | 《投资者关系管理制度 ...

证券代码：002399 证券简称：海普瑞 公告编号：2025-031 深圳市海普瑞药业集团股份有限公司 关于召开2025年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 16 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 16 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的 具体时间为 2025 年 12 月 16 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合 6、会议的股权登记日：2025 年 ...

二、董事会会议审议情况 证券代码：002399 证券简称：海普瑞 公告编号：2025-032 深圳市海普瑞药业集团股份有限公司 第六届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）第六届董事会第 十八次会议（以下简称"会议"）通知及议案于 2025 年 11 月 17 日以电子邮件 的形式发出，会议于 2025 年 11 月 24 日下午 14:00 在深圳市南山区松坪山朗山 路 21 号会议室以现场与通讯相结合方式召开。本次会议应参与表决董事 7 人， 实际参与表决董事 7 人，其中张平先生、黄鹏先生以通讯方式参与表决。公司高 级管理人员列席会议，会议由公司董事长李锂先生主持。本次会议的通知、召开 以及参与表决董事人数均符合相关法律法规及《公司章程》的有关规定。 经与会董事认真审议并通过了以下议案： 1、《关于取消监事会暨修订<公司章程>及相关治理制度的议案》 表决结果：7票同意、0票弃权、0票反对。 经审核，公司董事会同意对《公司章程》及相关治理制度进 ...

Core Viewpoint - The company, Haiprui, experienced a decline of 4.14% in stock price, with a trading volume of 53.28 million yuan and a total market capitalization of 16.977 billion yuan [1] Group 1: Company Overview - Haiprui, established in 1998 in Shenzhen, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][3] - The main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7] Group 2: Financial Performance - For the period from January to September 2025, Haiprui achieved operating revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to the parent company was 554 million yuan, a decrease of 29.04% year-on-year [7] - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with cumulative distributions of 514 million yuan over the past three years [8] Group 3: Market Position and Trends - As of the 2024 annual report, overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the yuan [3] - The company is involved in the mRNA vaccine development and production CDMO services through its subsidiary, Saiwan Bio, which supports the supply chain for multiple commercialized mRNA vaccines [2]

Core Viewpoint - Haiprime, a leading multinational pharmaceutical company, is benefiting from the depreciation of the RMB and has a strong focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2][3]. Company Overview - Haiprime was established in 1998 in Shenzhen and has both A and H share financing platforms. The company aims to provide high-quality, safe, and effective drugs and services to global patients [2]. - The main business segments of Haiprime include heparin raw materials, low molecular weight heparin products, and biopharmaceutical CDMO services [7]. Financial Performance - For the period from January to September 2025, Haiprime achieved a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%. However, the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - As of September 30, 2025, the overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. Shareholder Information - As of September 30, 2025, Haiprime had 27,000 shareholders, an increase of 2.60% from the previous period. The average number of circulating shares per person remained at zero [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 20, Haiprime's stock price increased by 0.42%, with a trading volume of 39.2348 million yuan and a turnover rate of 0.26%. The total market capitalization reached 17.71 billion yuan [1].

Core Viewpoint - The article discusses the recent performance and business operations of Haiprime, highlighting its position in the pharmaceutical industry and the impact of currency depreciation on its revenue [2][3]. Company Overview - Haiprime, established in 1998 and headquartered in Shenzhen, is a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development [2][7]. - The company's main revenue sources include formulations (63.06%), CDMO services (18.59%), and heparin sodium and low molecular weight heparin raw materials (16.05%) [7]. Financial Performance - For the period from January to September 2025, Haiprime reported a revenue of 4.194 billion yuan, representing a year-on-year growth of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - As of September 30, 2025, the overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Chinese yuan [3]. Market Activity - On November 17, Haiprime's stock price fell by 1.67%, with a trading volume of 49.2036 million yuan and a turnover rate of 0.32%, bringing the total market capitalization to 18.121 billion yuan [1]. - The stock has seen a net inflow of 1.2514 million yuan from major investors today, with no significant trend in buying or selling observed [4][5]. Technical Analysis - The average trading cost of Haiprime's shares is 11.59 yuan, with the stock price approaching a resistance level of 12.41 yuan, indicating potential for a price correction if it fails to break through this level [6]. Dividend Information - Since its A-share listing, Haiprime has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [8]. Shareholder Structure - As of September 30, 2025, Haiprime had 27,000 shareholders, with the Hong Kong Central Clearing Limited being the eighth largest shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].

11月17日，海普瑞盘中下跌2.07%，截至14:02，报12.30元/股，成交3908.08万元，换手率0.25%，总市 值180.48亿元。 资金流向方面，主力资金净流入201.77万元，大单买入567.39万元，占比14.52%，卖出365.62万元，占 比9.36%。 海普瑞今年以来股价涨17.82%，近5个交易日跌0.57%，近20日涨5.22%，近60日跌7.10%。 资料显示，深圳市海普瑞药业集团股份有限公司位于广东省深圳市南山区松坪山郎山路21号,香港湾仔 港湾道30号新鸿基中心47楼4724室，成立日期1998年4月21日，上市日期2010年5月6日，公司主营业务 涉及肝素钠原料药、下游低分子肝素产品的研究、生产和销售。主营业务收入构成为：制剂63.06%， CDMO18.59%，肝素钠以及低分子肝素钠原料药16.05%，其他2.30%。 海普瑞所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：原料药、H股、肝素、融 资融券、中盘等。 截至9月30日，海普瑞股东户数2.70万，较上期增加2.60%；人均流通股0股，较上期增加0.00%。2025年 1月-9月，海普瑞实现营业收入 ...

Core Viewpoint - Haiprime is a leading multinational pharmaceutical company with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue base [2][3]. Group 1: Company Overview - Haiprime was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The company’s main business segments include heparin, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7]. - As of September 30, 2025, Haiprime reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Group 2: Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Haiprime has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Activity - On November 12, Haiprime's stock rose by 0.16%, with a trading volume of 39.42 million yuan and a turnover rate of 0.26%, bringing the total market capitalization to 18.165 billion yuan [1]. - The stock has seen a net outflow of 534,600 yuan from major investors today, indicating a reduction in holdings over the past three days [4][5].

Core Viewpoint - The news highlights the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., emphasizing its strong international revenue and the impact of RMB depreciation on its financials [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [2]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [2][7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On November 10, the stock price of Hepalink increased by 0.90%, with a trading volume of 45.0469 million yuan and a turnover rate of 0.29%, bringing the total market capitalization to 18.15 billion yuan [1]. - The stock has seen a net outflow of 1.201 million yuan from major funds today, indicating a lack of strong buying interest [4][5]. Technical Analysis - The average trading cost of the stock is 11.57 yuan, with the current price near a support level of 12.33 yuan, suggesting potential for a rebound if this level holds [6].